Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Schizophrenia Clinical Trials

110 recruiting trials for Schizophrenia. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
110
Total Trials
110
Recruiting Now
8
Phase 3 Trials
10
Sponsors

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT05635266

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and...

Sponsor: Sanguine BiosciencesEnrolling: 200001 location
RECRUITINGNCT06182787

Development of a Model for Digital Monitoring of the Mental State of the Hospitalized Patient

This study presents the development and validation of a unique Digital Experience Sampling Method (ESM) questionnaire specifically adapted for monitoring changes in the mental...

Sponsor: Sheba Medical CenterEnrolling: 1301 location
RECRUITINGNCT06278532

Validation of the Lithuanian Version of the BNSS, CDSS, and the SCoRS

This study aims to validate the Lithuanian version of the Brief Negative Symptoms Scale, Calgary Depression Scale for Schizophrenia, and Schizophrenia Cognition Rating Scale in a...

Sponsor: Lithuanian University of Health SciencesEnrolling: 2002 locations
RECRUITINGPhase 4NCT05648591

Safety and Tolerability of Open-Labeled Iloperidone in Adolescents

To evaluate the safety and tolerability of iloperidone in adolescent patients with schizophrenia or bipolar I disorder for up to 52 weeks of treatment.

Sponsor: Vanda PharmaceuticalsEnrolling: 1009 locations
RECRUITINGNCT06071858

Enhanced Coordinated Specialty Care for Early Psychosis

The goal of this clinical trial is to compare engagement in treatment in coordinated specialty care (CSC) to five extra care elements (CSC 2.0) in first-episode psychosis. The...

Sponsor: Mclean HospitalEnrolling: 3505 locations
RECRUITINGNCT05866107

App and Body Fat Scale in the Management of Overweight Patients

This study tests whether using a health app (Huawei Health) and a smart body fat scale can help overweight patients with schizophrenia or bipolar disorder lose weight and stay...

Sponsor: Capital Medical UniversityEnrolling: 2041 location
RECRUITINGPhase 1NCT05025605

Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder

This is a study of the efficacy and safety of BXCL501 in children and adolescents with acute agitation and either bipolar disorder or schizophrenia.

Sponsor: BioXcel Therapeutics IncEnrolling: 1405 locations
RECRUITINGNCT03217110

Cerebellar Stimulation and Cognitive Control

The purpose of this study is to examine whether cerebellar stimulation can be used to improve cognitive deficits and mood in patients with schizophrenia, autism, bipolar disorder,...

Sponsor: Krystal Parker, PhDEnrolling: 2001 location
RECRUITINGNCT04946916

Neurofilament Light Chains and Cognitive Impairment in Chronic Psychiatric Disease

The validation of biomarkers allowing the discrimination of cognitive and behavioral disorders of psychiatric origin from those of neurodegenerative origin would facilitate...

Sponsor: Hôpital le VinatierEnrolling: 1202 locations
RECRUITINGNCT05945277

Critical Time Intervention-Peer Support

There is increasing awareness of the importance of providing mental health services and support that promote a recovery-oriented and human rights-based approach. A mental health...

Sponsor: Lisbon Institute of Global Mental Health - LIGMHEnrolling: 603 locations
RECRUITINGPhase 4NCT04580134

CLOZAPINE Response in Biotype-1

The CLOZAPINE study is designed as a multisite study across 5 sites and is a clinical trial, involving human participants who are prospectively assigned to an intervention. The...

Sponsor: University of Texas Southwestern Medical CenterEnrolling: 5245 locations
RECRUITINGNCT06740383

Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

The Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services (BICEPS) study aims to understand the early stages of psychotic disorders like Schizophrenia,...

Sponsor: Beth Israel Deaconess Medical CenterEnrolling: 3206 locations
RECRUITINGNCT06657430

A Study on the Preference of Risperidone Dosage Forms

This study aimed to understand patients' needs and preferences for antipsychotic dosage forms.

Sponsor: Shanghai Mental Health CenterEnrolling: 10001 location
RECRUITINGNCT06197048

Effect of Nutritional Counseling on Anthropometry and Biomarkers in Patients Diagnosed With Schizophrenia/Psychosis or...

The goal of this clinical trial is to compare the effect of nutritional counseling versus no treatment in patients with schizophenia or bipolar affective disorder. The main...

Sponsor: Vestre Viken Hospital TrustEnrolling: 402 locations
RECRUITINGNCT07316803

Group Intervention for Romantic Relationships in Young Adults With Severe Mental Illness

This study evaluates a group-based intervention designed to improve romantic and social relationship skills in adults living with a severe mental illness (SMI), such as...

Sponsor: Centre hospitalier de Ville-Evrard, FranceEnrolling: 202 locations
RECRUITINGPhase 4NCT07105111

A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain...

This study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMAT2 inhibitor.

Sponsor: Neurocrine BiosciencesEnrolling: 5019 locations
RECRUITINGNCT06758414

CBT-CP for Veterans With SMI

Chronic musculoskeletal pain has a highly negative impact on Veterans, especially those with serious mental illness (SMI). Chronic musculoskeletal pain leads to poorer mental and...

Sponsor: VA Office of Research and DevelopmentEnrolling: 1901 location
RECRUITINGNCT05491538

Acceptability and Feasibility of Work-Oriented Social-Cognitive Skills Training for Veterans With Serious Mental Illness

Many individuals with serious mental illness have difficulty accurately interpreting interpersonal cues and effectively engaging in social exchanges. Difficulties related to the...

Sponsor: VA Office of Research and DevelopmentEnrolling: 201 location
RECRUITINGNCT03601026

Genetic Counselling in the Prevention of Mental Health Consequences of Cannabis Use

Severe mental illness (SMI) refers to the most burdensome psychiatric conditions. The need to pre-empt the onset of SMI is pressing because once SMI develops, quality of life is...

Sponsor: Nova Scotia Health AuthorityEnrolling: 1201 location
RECRUITINGNCT06839950

Sensory Profile and Early Clinical Signs of Calm Room Users

This descriptive study aims primarily to characterize the sensory profile of patients in a closed psychiatric hospital unit who use a calming room. The main questions it aims to...

Sponsor: Centre Hospitalier EsquirolEnrolling: 801 location
RECRUITINGNCT06634446

Self-administered COgnitive Personalized Training in Early Psychosis

The overall objective of SCOPe is to improve early intervention in psychosis by providing an innovative eHealth tool that will enable personalized cognitive training, adapted to...

Sponsor: Centre Hospitalier St AnneEnrolling: 2401 location
RECRUITINGNCT05814913

Culturally Adapted Psychosocial Interventions for Early Psychosis in a Low-resource Setting

Primary Aims: To determine the clinical efficacy of Culturally adapted Cognitive Behavioral Therapy (CaCBT) and Culturally adapted Family Intervention (CulFI) compared to...

Sponsor: Pakistan Institute of Living and LearningEnrolling: 3901 location
RECRUITINGNCT07343193

Deprescribing Antipsychotics: a Multiple Case Study

The literature on antipsychotic deprescribing highlights the difficulty in establishing a clear consensus on the most optimal strategy due to the diversity of clinical situations...

Sponsor: University Hospital, Strasbourg, FranceEnrolling: 301 location
RECRUITINGNCT06568081

SloMo2: Implementation, Effectiveness, and Cost-effectiveness Study

Worries about harm from others (also known as paranoia) are common. Thinking fast or going on gut feelings is natural but can fuel these worries. For some, fast thinking and...

Sponsor: King's College LondonEnrolling: 1501 location
RECRUITINGNCT04300946

Time Prediction and Cerebellum: Magnetic Transcranial Stimulation (TMS) in Healthy Volunteers

The aim of the study is to check the role of the cerebellum in time prediction in healthy volunteers, by means of magnetic transcranial stimulation targeted on the cerebellum, and...

Sponsor: University Hospital, Strasbourg, FranceEnrolling: 481 location
RECRUITINGNCT06729541

Development and Application of Precision Treatment Strategies for Common Mental Disorders

Schizophrenia (SCH), major depressive disorder (MDD), and bipolar disorder (BPD) are prevalent, disabling psychiatric conditions that not only cause significant suffering for...

Sponsor: Peking UniversityEnrolling: 6001 location
RECRUITINGNCT06929533

Pharmacogenomics-Supported Psychotropic Prescribing Trial

Investigate the feasibility and utility of implementing pharmacogenetic testing for adults (aged 18 and older) seeking care for mental illness in Manitoba.

Sponsor: University of ManitobaEnrolling: 2002 locations
RECRUITINGPhase 2NCT06021197

NMDA-enhancing Treatment for Cognitive Dysfunction of Schizophrenia

Cognitive impairment, the core psychopathology of schizophrenia, usually persists in schizophrenia patients even during symptomatic remission. While cognitive impairment...

Sponsor: China Medical University HospitalEnrolling: 901 location
RECRUITINGNCT06945055

FAmily Engagement Strategy for Coordinated Specialty Care

Family members/support persons' engagement in mental health services has been linked to reduced burden and stress and improves engagement and outcomes in individuals in the early...

Sponsor: Washington State UniversityEnrolling: 9004 locations
RECRUITINGNCT07378150

Clay Therapy in Schizophrenia Patients

In recent years, art therapies have been discussed for their positive effects on mental disorders. One such therapy, clay therapy, is being studied to examine its effect on the...

Sponsor: Kutahya Health Sciences UniversityEnrolling: 171 location
RECRUITINGNCT07082777

Recovery in Telling Life Stories

This project tests the Recovery In Telling Life Stories (RETELL) intervention, aimed at supporting personal recovery in people with severe mental illness (SMI). While many of...

Sponsor: University of AarhusEnrolling: 201 location
RECRUITINGNCT06118268

iTBS to Enhance Social Cognition in People With Psychosis

The goal of this clinical trial is to examine if iTBS applied to the DMPFC improves social cognitive performance compared to sham stimulation in people diagnosed with...

Sponsor: Northwell HealthEnrolling: 1001 location
RECRUITINGPhase 3NCT06882785

A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia

The purpose of this study is to evaluate the efficacy and safety of KarXT in acutely psychotic Japanese adult participants with schizophrenia

Sponsor: Bristol-Myers SquibbEnrolling: 25020 locations
RECRUITINGNCT07058389

Synergy Between Physical Activity and Outdoor Green Environments to Reduce the Intensity of Negative Symptoms in...

Physical activity appears to be a novel and original adjunctive therapeutic approach in the management of patients with schizophrenia. It may help reduce schizophrenic symptoms,...

Sponsor: Centre Hospitalier Universitaire de Saint EtienneEnrolling: 451 location
RECRUITINGNCT04655235

Translational Investigation of the Glutamatergic and GABAergic System in Schizophrenia

In the last years, the imbalance between excitatory and inhibitory neuronal activity has come to the fore as a possible molecular disease mechanism of schizophrenia ....

Sponsor: RWTH Aachen UniversityEnrolling: 6003 locations
RECRUITINGPhase 2NCT07459647

A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia

ML-007C-MA-212 is a 52-week open-label study designed to evaluate the long-term safety, tolerability, and effectiveness of ML-007C-MA in participants with schizophrenia who have...

Sponsor: MapLight TherapeuticsEnrolling: 5005 locations
RECRUITINGPhase 3NCT06482554

Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.

This study is looking to determine if Lumateperone improves motivation in patients with schizophrenia or schizoaffective disorders who show high levels of apathy as judged by...

Sponsor: Louisiana State University Health Sciences Center ShreveportEnrolling: 801 location
RECRUITINGNCT06456983

Maintenance ElectroConvulsive Therapy in Clozapine RESISTant Schizophrenia - the MECT-RESIST Trial

Schizophrenia is one of the most severe and costliest mental disorders in terms of human suffering and societal expenditure. About 15-30% of patients do not respond to all known...

Sponsor: Central Institute of Mental Health, MannheimEnrolling: 14014 locations
RECRUITINGPhase 1NCT06058702

Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans

Cannabis is widely used worldwide and is associated with negative outcomes including cannabis use disorder (CanUD), psychosis, and cognitive impairment amongst others. Given the...

Sponsor: Yale UniversityEnrolling: 2151 location
RECRUITINGNCT06573320

Effect of Exercise on Clinical Symptoms, Cognitive Performance, and Quality of Life in Schizophrenia Patients Treated...

This prospective study aims to investigate the effects of exercise on clinical symptoms, cognitive performance, and quality of life in schizophrenia patients treated with...

Sponsor: Dr. Lutfi Kirdar Kartal Training and Research HospitalEnrolling: 601 location
RECRUITINGPhase 2NCT04745143

Monotherapy of an NMDA Enhancer for Schizophrenia

Previous studies found that some NMDA-enhancing agent was able to augment antioxidant activity and its adjunctive therapy was better than placebo in reducing clinical symptoms and...

Sponsor: China Medical University HospitalEnrolling: 801 location
RECRUITINGPhase 3NCT06894212

A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia

Evaluate the efficacy and safety of Ulotaront (SEP-363856) in acutely psychotic subjects with schizophrenia

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.Enrolling: 52220 locations
RECRUITINGNCT06508450

A Mental Health Services Engagement Program for Racial and Ethnic Minority Young Adults

Researchers aim to test a brief culturally-responsive young adult orientation program for community mental health services. They will conduct a 24-month randomized trial with 80...

Sponsor: New York UniversityEnrolling: 801 location
RECRUITINGNCT06484387

Study of Intra- and Interpersonal Multimodal Synchronizations in a Social Interaction in Individuals with a Diagnosis...

The aim of this study is to precisely identify deficits in intra- and interpersonal multimodal synchronizations during social interaction in individuals with schizophrenia (ISZ)....

Sponsor: University Hospital, MontpellierEnrolling: 1201 location
RECRUITINGNCT06650943

Nursing Intervention in Weight and Metabolic Syndrome Management in First-episode Psychosis (MetaKOP)

The goal of this clinical trial is to evaluate if a nursing intervention based on the carbohydrate-insulin model can effectively reduce weight and manage the risk of metabolic...

Sponsor: Hospital de BasurtoEnrolling: 881 location
RECRUITINGNCT05296720

EEG and Behavioral Correlates of Temporal Prediction in the Tactile Modality in Schizophrenia

Patients with schizophrenia have disturbances in their sense of self, particularly their bodily self. Disorders of the sense of self are central to schizophrenia and are of...

Sponsor: Centre Psychothérapique de NancyEnrolling: 681 location
RECRUITINGPhase 4NCT05282277

Examining the Effects of Estradiol on Neural and Molecular Response to Reward

This proposal will examine the effects of estradiol administration on perimenopausal-onset (PO) anhedonia and psychosis symptoms as well as on brain function using simultaneous...

Sponsor: University of North Carolina, Chapel HillEnrolling: 1031 location
RECRUITINGNCT07309172

KetoBrain: Brain Energy Metabolism in Schizophrenia

Objective The objective is to recruit antipsychotic-naïve patients at the first diagnosis with a first-episode schizophrenia disorder (FES) to study ketone metabolism of the brain...

Sponsor: Ole Köhler-ForsbergEnrolling: 341 location
RECRUITINGNCT06257056

Deep Brain Stimulation for Psychosis

There are three hypotheses proposed for this study: 1) Participants will report no unanticipated serious adverse events during the eight months of treatment. 2) Investigators will...

Sponsor: Bradley LegaEnrolling: 101 location
RECRUITINGNCT06048172

Effectiveness of Trauma Therapy Using Prolonged Exposure for Patients With PTSD and a Comorbid Psychotic Disorder

Psychosis patients with comorbid PTSD will be treated with trauma therapy.

Sponsor: Medicalschool HamburgEnrolling: 561 location

Showing 50 of 110 trials.Search all Schizophrenia trials

Frequently Asked Questions

There are currently 110 clinical trials for Schizophrenia, with 110 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Schizophrenia, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 8 Phase 3 trials for Schizophrenia, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.

this entity is one of the data points covered by this site’s U.S. clinical trials and research registries dataset. The detail above comes directly from the NIH ClinicalTrials.gov registry; the context that follows situates the headline numbers against the broader distribution across active and historical clinical trials.

Every number on this page links back to the NIH ClinicalTrials.gov registry; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.

Practical use of this page is in combination with the comparison and ranking pages elsewhere on the site, which surface the same data for this entity’s peers within active and historical clinical trials. A single-entity reading without peer context can be misleading when an entity is an outlier on one axis but typical on another.